Good news for Biocellvia. 2019 is beginning as well as possible. We are very proud to announce a new reference publicly. We have a collaboration with Ridgeline Therapeutics, an american biotech based in Texas. 2019 will be a key year for the development of Biocellvia with important events that will impact the company as key milestones.
2019 is a year full of promise for Biocellvia. Our technology is more and more acknowledged with major scientific articles that will be published this year. Biocellvia’s scientific team takes part to more and more scientific collaborations with research institutions implicated in NASH and pulmonary diseases.
In 2018, Pr. Yvon Julé, Biocellvia’s Chief Scientific Officer (CSO) co-signed scientific publications with Dr. Bernhard Ryffel, research director at CNRS, Dr. Stephanie Solier from Gustave Roussy (biggest european research institution dedicated to oncology). Pr. Isabelle Leclercq from Université of Louvain, key opinion leader on NASH, joined our scientific advisory board as Dr. Ryffel and Dr. Solier too.
Ridgeline Therapeutics is the first new reference of 2019. This collaboration highlights that Biocellvia’s technology is very competitive in North America, as Business France published it in 2018. Olivier Julé, Biocellvia’s CEO, took part to a business trip in San Diego in November 2018 to meet potential clients interested in our technology. We can already announce that one of these meetings enabled to changing a lead into a client. Biocellvia has begun a strong collaboration with a major californian biotech.
Last year, we could tell publicly that we had a collaboration with GSK. This “big pharma” is only one of our main references, and most of them prefer remaining confidential. 2019 will be surely a new step for Biocellvia with new references and strong partnerships. Our technology is more and more used by pharmaceutical industry. Biocellvia keeps on developping its market-driven technology. We keep on listening to potential collaborations, business and scientific opportunities.